Saxenda: Complete Guide to Liraglutide 3 mg for Weight Loss

What Is Saxenda and How Does It Work?

Saxenda is liraglutide 3 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist injected once daily under the skin. It mimics a naturally occurring hormone released after meals, slowing gastric emptying, increasing feelings of fullness, and reducing appetite signals in the hypothalamus. The net result is that patients eat less without feeling deprived by willpower alone.

Liraglutide shares its molecular backbone with native human GLP-1 but carries a C18 fatty acid chain that prolongs its half-life to roughly 13 hours, making once-daily dosing practical. The same active ingredient appears in Victoza (1.2 or 1.8 mg), which is FDA-approved for type 2 diabetes, but the 3 mg dose in Saxenda is the only liraglutide formulation specifically indicated for weight management.

The FDA approved Saxenda on December 23, 2014, making it the first GLP-1 agent approved in the United States specifically for chronic weight management rather than glycemic control. [1] That decade-plus track record means clinicians have more long-term observational data on Saxenda than on any other GLP-1 obesity agent currently on the market.

Saxenda is always prescribed alongside a reduced-calorie diet and increased physical activity. The medication does not replace lifestyle change; it makes sustained lifestyle change biologically more achievable by reducing the hunger drive that otherwise overrides behavioral intent.

Who Qualifies for Saxenda?

Saxenda is FDA-approved for two adult populations and one pediatric group. Adults qualify if they have a body mass index of 30 kg/m² or higher, or a BMI of 27 kg/m² or higher plus at least one weight-related condition such as type 2 diabetes, hypertension, or dyslipidemia. [1]

In 2020, the FDA extended the Saxenda label to adolescents aged 12 and older who weigh more than 60 kg and have an initial BMI at or above the 95th percentile for their age and sex. That made liraglutide 3 mg the first GLP-1 agent approved for pediatric obesity. [1]

Physicians typically consider Saxenda when lifestyle modification alone has not produced sufficient weight loss and when surgical options are not appropriate or desired. The AACE/ACE obesity clinical practice guidelines support pharmacotherapy as an adjunct to lifestyle therapy in patients who meet BMI criteria, noting that "antiobesity medications approved by the US FDA should be considered in appropriate candidates when lifestyle therapy alone does not achieve sufficient weight loss." [2]

Saxenda is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC), multiple endocrine neoplasia syndrome type 2 (MEN2), hypersensitivity to liraglutide, and pregnancy. It should not be combined with other GLP-1 receptor agonists or with insulin without careful medical oversight.

Saxenda Dosing Schedule

The standard dose titration begins at 0.6 mg daily for the first week, then increases by 0.6 mg every week until reaching the 3 mg maintenance dose at week five. The slow escalation is not cosmetic; it substantially reduces early gastrointestinal side effects. Patients who cannot tolerate 3 mg may stay at 2.4 mg, though published efficacy data are based on the full 3 mg dose.

| Week | Daily Dose | |------|-----------| | 1 | 0.6 mg | | 2 | 1.2 mg | | 3 | 1.8 mg | | 4 | 2.4 mg | | 5 onward | 3.0 mg |

Injections are given at any time of day, independent of meals, in the abdomen, thigh, or upper arm. Rotate sites within the same region to minimize subcutaneous nodule formation. The Saxenda pen delivers prefilled, premixed solution and does not require reconstitution.

If a patient has not lost at least 4 percent of baseline body weight after 16 weeks at the full 3 mg dose, the FDA label advises discontinuing Saxenda because the probability of achieving clinically meaningful weight loss is low. [1]

What Weight Loss Can Patients Expect on Saxenda?

The SCALE Obesity and Prediabetes trial (N=3,731), the key phase 3 study supporting FDA approval, showed that patients on liraglutide 3 mg lost a mean of 8.4 kg (8.0 percent of body weight) over 56 weeks compared with 2.8 kg (2.6 percent) for placebo, with 63.2 percent of liraglutide participants losing at least 5 percent of body weight versus 27.1 percent for placebo. [3]

Those are meaningful numbers. But they also sit below what newer agents produce, and that comparison matters for prescribing decisions.

The STEP-8 head-to-head trial (N=338, JAMA 2022) compared semaglutide 2.4 mg (Wegovy) directly against liraglutide 3 mg (Saxenda) over 68 weeks. Semaglutide produced a mean weight loss of 15.8 percent versus 6.4 percent for liraglutide, a difference of 9.4 percentage points (P<0.001). [4] Semaglutide also showed a larger proportion of patients achieving 10, 15, and 20 percent weight-loss thresholds.

SURMOUNT-1 (N=2,539, NEJM 2022) tested tirzepatide (the active ingredient in Mounjaro and Zepbound) and found that the 15 mg dose produced a mean weight reduction of 22.5 percent at 72 weeks in adults without diabetes. [5] That is roughly three to four times the weight loss seen with Saxenda in its key trial.

So the hierarchy based on trial data is roughly: tirzepatide (Zepbound/Mounjaro) at 15 mg produces the most weight loss, followed by semaglutide 2.4 mg (Wegovy), then liraglutide 3 mg (Saxenda). Saxenda still achieves clinically significant weight loss, and its older approval date and more extensive real-world data set remain genuine advantages for certain patients and prescribers.

Saxenda vs. Wegovy: How Do They Compare?

Both Saxenda and Wegovy are manufactured by Novo Nordisk and belong to the same drug class. The differences are the active molecule, the injection frequency, and the amount of weight loss patients can typically expect.

Wegovy contains semaglutide at 2.4 mg, injected once weekly. STEP-1 (N=1,961, NEJM 2021) showed a mean weight loss of 14.9 percent at 68 weeks versus 2.4 percent for placebo, with 86.4 percent of semaglutide participants losing at least 5 percent of body weight. [6] Wegovy also carries an FDA indication for cardiovascular risk reduction after the SELECT trial (N=17,604) showed a 20 percent relative risk reduction in major adverse cardiovascular events in overweight or obese adults with established cardiovascular disease. [7]

The STEP-5 trial extended semaglutide data to 104 weeks (two years) and found sustained mean weight loss of 15.2 percent in the semaglutide group versus 2.6 percent for placebo, confirming that Wegovy's effects are durable with continued use. [8]

For patients who prefer once-daily administration, have previously responded to liraglutide, or face cost barriers to semaglutide, Saxenda remains a reasonable choice. The once-daily schedule also allows for more granular dose adjustments during the titration phase, which some clinicians find useful in patients with heightened GI sensitivity.

Saxenda vs. Ozempic: Clarifying the Confusion

Ozempic (semaglutide 0.5, 1, or 2 mg) is often confused with Saxenda and Wegovy. Ozempic is FDA-approved specifically for type 2 diabetes management and cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease. It is not FDA-approved for weight management as a standalone obesity therapy, though it does produce weight loss as a secondary effect.

Prescribing Ozempic purely for weight loss in a patient without diabetes is an off-label use. Wegovy is the correct on-label semaglutide choice for weight management, as it uses the 2.4 mg dose studied in the STEP program.

Saxenda, by contrast, has had a dedicated obesity indication since 2014. Patients choosing between Saxenda and Ozempic off-label for weight loss are comparing a once-daily FDA-approved obesity drug against an off-label use of a once-weekly diabetes drug, two situations that are not directly analogous from a regulatory or insurance-coverage standpoint.

Saxenda vs. Mounjaro and Zepbound

Mounjaro (tirzepatide) and Zepbound (tirzepatide) contain the same active ingredient. Mounjaro is FDA-approved for type 2 diabetes; Zepbound is FDA-approved for chronic weight management. Tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it activates both the glucose-dependent insulinotropic polypeptide receptor and the GLP-1 receptor simultaneously, a mechanism Saxenda does not have.

That dual agonism likely explains tirzepatide's superior weight-loss data. SURMOUNT-1 results at the 15 mg dose showed 22.5 percent mean weight loss versus 2.5 percent for placebo at 72 weeks. [5] SURMOUNT-4 (JAMA 2024, N=670) further demonstrated that patients who lost weight on tirzepatide during a 36-week lead-in and then continued the drug maintained a further 5.5 percent weight reduction over the next 52 weeks, whereas patients switched to placebo regained an average of 14 percent of body weight. [9]

Saxenda's comparative disadvantage in weight loss does not mean it is without clinical value. Mounjaro and Zepbound are newer agents with shorter post-market surveillance windows. Saxenda has more than a decade of real-world data supporting its safety profile. For patients in whom tirzepatide is contraindicated, unaffordable, or unavailable, liraglutide 3 mg is a proven, guideline-supported alternative.

Side Effects and Safety Profile of Saxenda

The most common side effects of Saxenda are gastrointestinal and dose-dependent. Nausea affects approximately 39 percent of patients on liraglutide 3 mg compared with 14 percent on placebo in the SCALE trial; vomiting occurred in 15 percent versus 4 percent; diarrhea in 21 percent versus 10 percent; and constipation in 19 percent versus 9 percent. [3] Most GI symptoms peak during the titration phase and diminish after reaching the maintenance dose.

Clinically significant but less common risks include:

• Pancreatitis. The Saxenda label carries a warning. Patients should discontinue the drug if pancreatitis is suspected and not restart it after confirmation. [1]
• Gallbladder disease. Cholelithiasis and cholecystitis occur at higher rates in patients losing weight on GLP-1 agents compared with those losing weight through lifestyle alone. Rapid weight loss accelerates gallstone formation regardless of medication.
• Thyroid C-cell tumors. Rodent studies showed a dose-dependent increase in thyroid C-cell adenomas and carcinomas with liraglutide. Whether this translates to human risk remains uncertain; the FDA requires a black-box warning and mandates that the drug not be used in patients with a personal or family history of MTC or MEN2. [1]
• Hypoglycemia. In patients without type 2 diabetes, hypoglycemia is rare on Saxenda alone. Risk rises when Saxenda is combined with insulin secretagogues.
• Heart rate. Liraglutide increases mean resting heart rate by approximately 2 to 3 beats per minute. The clinical significance is debated, but monitoring is advisable in patients with pre-existing tachyarrhythmias.

Saxenda is classified as FDA Pregnancy Category X equivalent under current labeling, meaning it should be stopped at least two months before attempting conception. [1]

Saxenda and Cardiovascular Outcomes

The LEADER cardiovascular outcomes trial tested liraglutide 1.8 mg (Victoza dose, not the 3 mg Saxenda dose) in 9,340 patients with type 2 diabetes and high cardiovascular risk. Liraglutide reduced the rate of major adverse cardiovascular events by 13 percent relative to placebo (P<0.001 for non-inferiority, P=0.01 for superiority). [10]

No comparable large-scale cardiovascular outcomes trial has been completed specifically for liraglutide 3 mg in a population without diabetes. The SELECT trial confirmed cardiovascular benefits for semaglutide 2.4 mg (Wegovy) in patients without diabetes. [7] Saxenda does not currently share that same label claim.

For patients with obesity and established atherosclerotic cardiovascular disease, Wegovy's SELECT-derived cardiovascular indication makes it the preferred GLP-1 agent when tolerability and access permit.

Does Saxenda Work in Adolescents?

Yes. The SCALE Teens trial (N=251, NEJM 2020) tested liraglutide 3 mg in adolescents aged 12 to 17 with obesity. At 56 weeks, BMI standard deviation score (SDS) decreased by 0.22 in the liraglutide group versus an increase of 0.22 in the placebo group (P<0.001). [11] The FDA used this data to approve Saxenda for pediatric use in 2020.

Side effects in adolescents mirror those in adults, with nausea being the most common reason for discontinuation. Pediatric prescribers should note that the dose titration schedule is identical to that used in adults.

What Happens When You Stop Saxenda?

Weight regain after stopping Saxenda is a documented pattern, not an exception. The SCALE program included a withdrawal phase; patients who discontinued liraglutide regained approximately two-thirds of their lost weight within 12 weeks. [3] This mirrors findings across all GLP-1 agents: the drug addresses a chronic biological condition, and stopping treatment typically allows that condition to reassert itself.

Clinicians should frame Saxenda as long-term or indefinite therapy for most patients, not a short-term course. The FDA label includes no stated treatment duration limit.

The HealthRX clinical team uses a structured response-monitoring framework at weeks 4, 8, and 16 for patients on Saxenda. If body weight has not decreased by at least 2 percent at week 8 and 4 percent at week 16 relative to the start of the 3 mg maintenance dose, the framework flags the patient for discussion about transitioning to a higher-efficacy agent such as semaglutide 2.4 mg or tirzepatide, assuming no contraindications exist. This approach aligns with the FDA's 16-week non-responder stopping rule while giving clinicians a structured earlier checkpoint to act on.

Saxenda Cost, Insurance Coverage, and Alternatives

Saxenda's list price in the United States is approximately $1,400 per month without insurance. Novo Nordisk offers a savings card that may reduce costs for commercially insured patients to as low as $25 per month, though this does not apply to government-funded insurance programs such as Medicare or Medicaid.

Insurance coverage for weight-loss medications remains inconsistent. Many commercial plans now cover at least one GLP-1 agent for obesity, but formulary placement and prior authorization requirements vary widely. Patients who meet criteria but face coverage denials should ask their prescriber about a letter of medical necessity and may consider formal appeals.

Compounded liraglutide is available through some telehealth pharmacies at lower cost. Compounded versions are not FDA-approved, do not use the same manufacturing standards as the Novo Nordisk product, and carry unknown potency and sterility risks. Patients considering compounded liraglutide should discuss this distinction explicitly with their prescriber.

Saxenda Compared to Other Weight Loss Drugs: Quick Reference

| Drug | Active Ingredient | Frequency | Approval Indication | Mean Weight Loss (Key Trial) | |------|------------------|-----------|--------------------|---------------------------------| | Saxenda | Liraglutide 3 mg | Daily | Obesity/overweight | ~8% at 56 weeks [3] | | Wegovy | Semaglutide 2.4 mg | Weekly | Obesity/overweight + CV | 14.9% at 68 weeks [6] | | Ozempic | Semaglutide 0.5-2 mg | Weekly | Type 2 diabetes | Varies by dose | | Zepbound | Tirzepatide 2.5-15 mg | Weekly | Obesity/overweight | 22.5% at 72 weeks (15 mg) [5] | | Mounjaro | Tirzepatide 2.5-15 mg | Weekly | Type 2 diabetes | Varies by dose |

Practical Tips for Starting Saxenda

Patients starting Saxenda should store unused pens refrigerated between 36°F and 46°F (2°C and 8°C). An in-use pen may be kept at room temperature up to 77°F (25°C) for 30 days. Never freeze the pen; frozen liraglutide solution should be discarded.

Injecting Saxenda immediately before bed can reduce the subjective burden of nausea because peak plasma concentrations coincide with sleep. Some patients find morning injection preferable; the key is consistency. Missing one dose is not clinically significant; simply resume the next scheduled injection and do not double up.

Patients should contact their prescriber promptly if they experience persistent severe abdominal pain (possible pancreatitis), vision changes (possible diabetic retinopathy progression if they have diabetes), palpitations, or signs of allergic reaction such as rash, facial swelling, or difficulty breathing.